All In Biotech

Drug Trial Radar · NCT05165485

Phase 4 COPD and Suboptimal Inspiratory Flow Rate

A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered Via Standard Jet Nebulizer or Tiotropium Delivered Via a Dry Powder Inhaler (Spiriva® HandiHaler®)

Last checked: Nov 19, 2026Latest source record: Dec 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 404 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

404

Actual

Start

Jan 7, 2022

Primary completion

Nov 13, 2023

Study completion Nov 20, 2023

Sponsor

Lead sponsor
Theravance BiopharmaIndustry
Sponsor type
Industry
Collaborators
Viatris Inc.
First posted
Dec 21, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study is a randomized, double-blind, double-dummy, parallel-group study evaluating efficacy and safety of revefenacin vs. tiotropium in adults with severe to very severe COPD and suboptimal PIFR.

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • RevefenacinDrug

    Revefenacin 175 mcg administered once daily for 84 days via nebulization

  • TiotropiumDrug

    Tiotropium 18 mcg administered once daily for 84 days via Spiriva HandiHaler®

  • Revefenacin PlaceboDrug

    Placebo for Revefenacin administered once daily for 84 days via nebulization

  • Tiotropium PlaceboDrug

    Placebo for Tiotropium administered once daily for 84 days via Spiriva HandiHaler®

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. FEV1Time frame: Baseline, Day 85 following 84 days of dosing

Locations

76 sites in 1 country. Site status is shown where the registry gives one.

  • Theravance Biopharma Investigational Site

    Jasper, Alabama

  • Theravance Biopharma Investigational Site

    Phoenix, Arizona

  • Theravance Biopharma Investigational Site

    Tucson, Arizona

  • Theravance Biopharma Investigational Site

    Newport Beach, California

  • Theravance Biopharma Investigational Site

    San Diego, California

  • Theravance Biopharma Investigational Site

    Stockton, California

  • Theravance Biopharma Investigational Site

    Upland, California

  • Theravance Biopharma Investigational Site

    Lakewood, Colorado

  • Theravance Biopharma Investigational Site

    Brandon, Florida

  • Theravance Biopharma Investigational Site

    Clearwater, Florida

  • Theravance Biopharma Investigational Site site 2

    Clearwater, Florida

  • Theravance Biopharma Investigational Site

    Clearwater, Florida

  • Theravance Biopharma Investigational Site

    Daytona Beach, Florida

  • Theravance Biopharma Investigational Site

    Leesburg, Florida

  • Theravance Biopharma Investigational Site

    Miami, Florida

  • Theravance Biopharma Investigational Site

    Miami, Florida

  • Theravance Biopharma Investigational Site

    Orlando, Florida

  • Theravance Biopharma Investigational Site

    Ormond Beach, Florida

  • Theravance Biopharma Investigational Site

    Sarasota, Florida

  • Theravance Biopharma Investigational Site

    Tampa, Florida

  • Theravance Biopharma Investigational Site

    Winter Park, Florida

  • Theravance Biopharma Investigational Site

    Chicago Ridge, Illinois

  • Theravance Biopharma Investigational Site

    River Forest, Illinois

  • Theravance Biopharma Investigational Site

    Hammond, Indiana

  • Theravance Biopharma Investigational Site

    Valparaiso, Indiana

  • Theravance Biopharma Investigational Site

    Annapolis, Maryland

  • Theravance Biopharma Investigational Site

    Columbia, Maryland

  • Theravance Biopharma Investigational Site

    Oxon Hill, Maryland

  • Theravance Biopharma Investigational Site

    Towson, Maryland

  • Theravance Biopharma Investigational Site

    North Dartmouth, Massachusetts

  • Theravance Biopharma Investigational Site

    Farmington Hills, Michigan

  • Theravance Biopharma Investigational Site

    Saint Charles, Missouri

  • Theravance Biopharma Investigational Site

    St Louis, Missouri

  • Theravance Biopharma Investigational Site

    Missoula, Montana

  • Theravance Biopharma Investigational Site

    Las Vegas, Nevada

  • Theravance Biopharma Investigational Site

    Albuquerque, New Mexico

  • Theravance Biopharma Investigational Site

    Bronxville, New York

  • Theravance Biopharma Investigational Site

    Schenectady, New York

  • Theravance Biopharma Investigational Site

    Charlotte, North Carolina

  • Theravance Biopharma Investigational Site

    Hickory, North Carolina

Showing 40 of 76 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.